Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Standard Biotools Inc (LAB)

Standard Biotools Inc (LAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 718,460
  • Shares Outstanding, K 372,259
  • Annual Sales, $ 106,340 K
  • Annual Income, $ -74,660 K
  • EBIT $ -164 M
  • EBITDA $ -148 M
  • 60-Month Beta 1.61
  • Price/Sales 6.37
  • Price/Cash Flow N/A
  • Price/Book 1.33

Options Overview Details

View History
  • Implied Volatility 87.85% ( -16.11%)
  • Historical Volatility 79.77%
  • IV Percentile 69%
  • IV Rank 26.31%
  • IV High 319.12% on 12/22/23
  • IV Low 5.28% on 08/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 3,944
  • Open Int (30-Day) 3,485

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +58.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4600 +32.19%
on 11/19/24
2.2600 -14.60%
on 11/11/24
-0.2200 (-10.23%)
since 11/08/24
3-Month
1.4600 +32.19%
on 11/19/24
2.3200 -16.81%
on 11/07/24
-0.0600 (-3.02%)
since 09/09/24
52-Week
1.2100 +59.50%
on 08/01/24
3.0400 -36.51%
on 04/09/24
-0.3100 (-13.84%)
since 12/08/23

Most Recent Stories

More News
Standard BioTools Appoints Alex Kim as Chief Financial Officer

LAB : 1.9300 (+6.04%)
Standard BioTools to Participate in Upcoming Investor Conferences

LAB : 1.9300 (+6.04%)
Standard BioTools: Q3 Earnings Snapshot

Standard BioTools: Q3 Earnings Snapshot

LAB : 1.9300 (+6.04%)
Standard BioTools Reports Third Quarter 2024 Financial Results

LAB : 1.9300 (+6.04%)
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

LAB : 1.9300 (+6.04%)
Standard BioTools: Q2 Earnings Snapshot

Standard BioTools: Q2 Earnings Snapshot

LAB : 1.9300 (+6.04%)
Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

APRN : 12.99 (-0.08%)
FRGI : 8.49 (unch)
LAB : 1.9300 (+6.04%)
CPRI : 22.22 (-0.36%)
LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic

/PRNewswire/ -- Shareholder rights law firm Julie & Holleman LLP is investigating potential breaches of fiduciary duty relating to the proposed merger between...

LAB : 1.9300 (+6.04%)
SLGC : 2.10 (-4.55%)
Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update

Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global  Upgraded management team...

LAB : 1.9300 (+6.04%)
Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to...

LAB : 1.9300 (+6.04%)

Business Summary

Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm...

See More

Key Turning Points

3rd Resistance Point 2.2700
2nd Resistance Point 2.1300
1st Resistance Point 2.0300
Last Price 1.9300
1st Support Level 1.7900
2nd Support Level 1.6500
3rd Support Level 1.5500

See More

52-Week High 3.0400
Fibonacci 61.8% 2.3409
Fibonacci 50% 2.1250
Last Price 1.9300
Fibonacci 38.2% 1.9091
52-Week Low 1.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar